- Adult-Onset Still’s Disease (AOSD)
- Arthritis
- Ankylosing Spondylitis
- Bronchiectasis
- Chronic Obstructive Pulmonary Disease
- Chronic Skin Conditions
- Cluster Headache
- Complex Regional Pain Syndrome
- Eczema
- Ehlers Danlos Syndrome
- Endometriosis
- Fibromyalgia
- Gout
- Headaches
- HIV
- Joint Hypermobility Syndrome
- Long Covid
- Lower Back Pain
- Lupus
- Mast Cell Activation Syndrome (MCAS)
- Migraines
- Mixed Connective Tissue Disease
Releaf Blog
Discover helpful insights on health, wellness, and medical cannabis in our blogs. Explore practical articles covering general medical cannabis info, tips for staying well, and how medical cannabis can assist with specific health conditions.
Latest
Releaf and brainstrust: A brand-new partnership to support brain tumour patients
We are proud to announce a new partnership between Releaf and brainstrust, the UK charity supporting people affected by a brain tumour. Together, we want to make sure that anyone living with a brain tumour has access to compassionate, expert care through the most trusted medical cannabis clinic in the UK. Here is what the partnership means and how patients currently in treatment can get in touch.
Quick reads
Articles
National Cancer Survivor’s Day: How medical cannabis supports patients living with cancer
Living with cancer involves far more than the diagnosis itself, with symptoms like pain, nausea and poor sleep affecting everyday life. For National Cancer Survivors' Day 2026, this guide explores how medical cannabis may support eligible patients in managing cancer-related symptoms as part of a wider, clinician-led care plan.
What 24 cancer patients told us about medical cannabis for symptom relief: findings from Releaf's 2025 UK patient survey
Releaf's 2025 UK Medical Cannabis Patient Survey is the largest survey of active UK medical cannabis patients ever conducted. Of the 1,669 respondents, 24 selected cancer-related as their primary condition category. All 24 reported an improvement in quality of life, 83.3% rated their treatment extremely, very, or moderately effective, 83.3% experienced no side effects, and 95.8% would recommend medical cannabis to others. Here is what these patients told us about managing their symptoms alongside conventional oncology care.
114 patients picked up the phone: Inside the first four months of Releaf Protect legal helpline data
In the first four months of 2026, 114 Releaf patients picked up the phone to the Releaf Protect legal helpline. Across employment disputes, criminal procedure questions, and roadside concerns, the data reveals the everyday reality of being a legal medical cannabis patient in a system still catching up with the law.
Decoding Cannabis: what the first placebo-controlled cannabis migraine trial means for patients in 2026
The first randomised, placebo-controlled trial of vaporised cannabis for migraine attacks has finally been published. Researchers at UC San Diego compared THC, CBD, a balanced combination, and placebo across 247 treated migraines. The balanced ratio came out clearly ahead, with sustained benefit at 24 and 48 hours and no serious adverse events. We unpack what the trial proves, where it falls short, and how the results sit alongside Releaf's UK patient survey data on medical cannabis for migraine.









